Osimertinib (AZD9291)
Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
| Supplier | Selleck Chemicals |
|---|---|
| Product # | S7297 |
| Sku # | S7297-5mg |
| Pricing | 5mg, $70.00 |
Citations for this product:
-
bioRxiv - Cancer Biology 2020Quote: ... and osimertinib (S7297, Selleck Chemicals) were dissolved in DMSO to prepare 0.4 M stock solutions ...
-
bioRxiv - Genetics 2021Quote: ... and osimertinib (S7297) were purchased from Selleck Chemicals and gefitinib (SML1657 ...
-
bioRxiv - Cancer Biology 2019Quote: ... cells were treated for 48 hours (day 2) with DMSO (TN) or for 7 and 19 days with 2µM Osimertinib (Selleck Chemicals LLC, S7297) with replenishment of drug every 3-4 days (RD) ...
-
bioRxiv - Cancer Biology 2022Quote: ... ralimetinib (Selleckchem; Cat. No. S1494) and osimertinib (Selleckchem; Cat. No. S7297) were purchased from Selleck Chemicals (Houston, TX, USA). For adherent cancer cell lines ...